Clinical Trials
92 trialsSTARTRK-2
Hoffmann-La Roche
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
National Institutes of Health Clinical Center (CC)
A Phase â… Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Managed Access Programs for LDK378, Ceritinib
Novartis
Crizotinib Continuation Clinical Study
Pfizer
COSMIC
Wake Forest University Health Sciences
Study of Oral MRT-2359 in Selected Cancer Patients
Monte Rosa Therapeutics, Inc
DETERMINE
Cancer Research UK
SELECT-CAR-NK
Essen Biotech
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
ARC-12
Arcus Biosciences, Inc.
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Meteor 1
GlaxoSmithKline
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Janssen Research & Development, LLC
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics, Inc.
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
CytomX Therapeutics
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
IDeATIon
Assistance Publique - Hôpitaux de Paris
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NovalGen Ltd.
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Eastern Cooperative Oncology Group
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
AIDS Malignancy Consortium
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Takeda
Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function
GlaxoSmithKline
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
ONCODAGE
Institut Bergonié
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
EBUS
Mid and South Essex NHS Foundation Trust
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.